Literature DB >> 16338215

Redox-reactive autoantibodies: detection and physiological relevance.

John A McIntyre1, Dawn R Wagenknecht, W Page Faulk.   

Abstract

We recently described a hitherto unrecognized family of autoantibodies that become unmasked (detectable) subsequent to oxidation-reduction (redox) reactions. These masked redox-reactive autoantibodies are not detectable by using conventional immunoassays. Additional experimentation has demonstrated that autoantibodies in the blood of patients with autoimmune diseases can be masked (become undetectable) by exposure to oxidizing agents. Simultaneous masking and unmasking of different autoantibodies in a given patient's serum or plasma is evidence that immune complexes are not the source of redox-reactive autoantibodies. We propose that a mechanism responsible for unmasking-masking antibody specificities requires nitrosylation of tyrosine residues in the hypervariable or complementarity determining regions of the antibodies' antigen-binding sites. Other laboratories, selected by us for their respective expertise, have studied our redox-reacted and control serum and/or antibody preparations and have found an expanding array of autoantibody specificities. The gathering data suggest that certain autoimmune diseases may involve redox disorders rather than a failure to deplete, suppress, tolerate or divert self-directed B cell activity. The persistence and fluctuation of redox-reactive autoantibodies suggest that they are manifestations of an as yet undefined natural selective pressure on the evolution of the immunological system. We propose that they are the "contrivances" suggested by Paul Ehrlich more than a hundred years ago, and that these antibodies perform important physiological and pathophysiological functions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16338215     DOI: 10.1016/j.autrev.2005.07.009

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  9 in total

Review 1.  Do antiphospholipid antibodies develop for a purpose?

Authors:  Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2006-04       Impact factor: 4.592

Review 2.  Redox-reactive autoantibodies: biochemistry, characterization, and specificities.

Authors:  John A McIntyre; W Page Faulk
Journal:  Clin Rev Allergy Immunol       Date:  2009-08       Impact factor: 8.667

3.  Autoimmune reactivity of IgM acquired after oxidation.

Authors:  Jasna Omersel; Ivica Avberšek-Lužnik; Pegi Ahlin Grabnar; Tanja Kveder; Blaž Rozman; Borut Božič
Journal:  Redox Rep       Date:  2011       Impact factor: 4.412

4.  Antiphospholipid autoantibodies as blood biomarkers for detection of early stage Alzheimer's disease.

Authors:  John A McIntyre; Curtis J Ramsey; Bruce D Gitter; Andrew J Saykin; Dawn R Wagenknecht; Paul A Hyslop
Journal:  Autoimmunity       Date:  2015-02-12       Impact factor: 2.815

5.  Natural hidden autoantibodies to tissue transglutaminase cross-react with fibrinogen.

Authors:  Ingrid M Zöller-Utz; Birgit Esslinger; Anja Schulze-Krebs; Walburga Dieterich
Journal:  J Clin Immunol       Date:  2009-11-27       Impact factor: 8.317

6.  Intravenous Immunoglobulin with Enhanced Polyspecificity Improves Survival in Experimental Sepsis and Aseptic Systemic Inflammatory Response Syndromes.

Authors:  Iglika Djoumerska-Alexieva; Lubka Roumenina; Anastas Pashov; Jordan Dimitrov; Maya Hadzhieva; Sandro Lindig; Elisaveta Voynova; Petya Dimitrova; Nina Ivanovska; Clemens Bockmeyer; Zvetanka Stefanova; Catherine Fitting; Markus Bläss; Ralf Claus; Stephan von Gunten; Srini Kaveri; Jean-Marc Cavaillon; Michael Bauer; Tchavdar Vassilev
Journal:  Mol Med       Date:  2016-03-31       Impact factor: 6.354

Review 7.  Breaking the law: unconventional strategies for antibody diversification.

Authors:  Alexia Kanyavuz; Annaelle Marey-Jarossay; Sébastien Lacroix-Desmazes; Jordan D Dimitrov
Journal:  Nat Rev Immunol       Date:  2019-06       Impact factor: 53.106

8.  Functional Changes of Therapeutic Antibodies upon Exposure to Pro-Oxidative Agents.

Authors:  Maxime Lecerf; Robin Lacombe; Alexia Kanyavuz; Jordan D Dimitrov
Journal:  Antibodies (Basel)       Date:  2022-02-02

Review 9.  Antiphospholipid syndrome.

Authors:  Gerard Espinosa; Ricard Cervera
Journal:  Arthritis Res Ther       Date:  2008-12-15       Impact factor: 5.156

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.